Unitaid is a hosted partnership of the World Health Organization (WHO). It is based in Geneva, Switzerland. The operations of the secretariat are administered in accordance with Unitaid’s constitution and WHO rules.
Unitaid is an international organisation that invests in innovations to prevent, diagnose and treat HIV/AIDS, tuberculosis and malaria more quickly, affordably and effectively. We also work to improve access to diagnostics and treatment for HIV co-infections such as hepatitis C and human papillomavirus (HPV).
Unitaid provides health partners with short-term financial grants, targeted to achieve maximum impact.
Unitaid researches and identifies new health solutions with potential to alleviate the burden of HIV/AIDS, tuberculosis and malaria, as well as HIV co-infections including hepatitis C.
Through calls for proposals, Unitaid finds partners best qualified to put key innovations into practice.
These partners receive grants from Unitaid to fast-track access and reduce costs of more effective medicines, technologies and systems.
In this way, Unitaid’s investments establish the viability of health innovations, allowing partner organisations to make them widely available.
Since its establishment in , Unitaid has received about US $3 billion in contributions from donors. Unitaid’s main donors are France, the United Kingdom, Norway, the Bill & Melinda Gates Foundation, Brazil, Spain, the Republic of Korea, and Chile.
A key source of income is innovative financing, specifically the solidarity levy on airline tickets implemented by France, which was later adopted by a number of other countries (including Cameroon, Chile, Congo, Guinea, Madagascar, Mali, Mauritius, Niger, and the Republic of Korea).